Address
1 Avenue d'Ester - 87280 LIMOGES
Email
info@curlim.eu
We are pleased to announce our participation in the 1st Annual European Neuroscience Innovation Forum, taking place in Zurich from March 3 to 5, 2026.
During the event, we will be pitching CLM001, our breakthrough nanodrug targeting the root causes of Charcot-Marie-Tooth disease type 1A (CMT1A).
CLM001 is being developed for the treatment of CMT1A, the most common inherited peripheral neuropathy, characterized by progressive demyelination and axonal damage.
During our presentation, we will share insights into our drug candidate, our scientific approach, and the latest advancements in our development program.
In addition, Laurent Richebourg, CEO of CURLIM, will participate in a panel discussion :
🗓Tuesday, March 3 at 14:25 – “Developing Next-Gen Therapies for Rare Neurodegenerative Disorders: Including ALS & HD” Chaired by Thierry Laugel.
If you will be attending the forum in Zurich, we would be pleased to connect.
💬 Contact us to schedule a meeting.